WKP|Q54281623

Search

Select Field:

Select Index:

Search Terms:

Leader		00000nz a2200037n 45 0
001		WKP\|Q54281623 (VIAF cluster) (Authority/Source Record)
003		WKP
005		20241221010840.0
008		241221nneanz\|\|abbn n and d
035		‎‡a (WKP)Q54281623‏
024		‎‡a 0000-0001-8557-473X‏ ‎‡2 orcid‏
035		‎‡a (OCoLC)Q54281623‏
100	0	‎‡a Christoph R. Werner‏ ‎‡c deutscher Arzt‏ ‎‡9 de‏
375		‎‡a 1‏ ‎‡2 iso5218‏
400	0	‎‡a Christoph R. Werner‏ ‎‡c German physician‏ ‎‡9 en‏
400	0	‎‡a Christoph R Werner‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
400	0	‎‡a Christoph R. Werner‏ ‎‡c mjek gjerman‏ ‎‡9 sq‏
670		‎‡a Author's [Acute kidney injury in liver failure].‏
670		‎‡a Author's CCK inhibits the orexigenic effect of peripheral ghrelin‏
670		‎‡a Author's Choledochoduodenal fistula after liver transplantation.‏
670		‎‡a Author's Efficacy and safety of telaprevir‏
670		‎‡a Author's Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment.‏
670		‎‡a Author's Epidemiology and Genotyping of Patients with Chronic Hepatitis B: Genotype Shifting Observed in Patients from Central Europe‏
670		‎‡a Author's Feasibility of telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: SVR 24 results‏
670		‎‡a Author's First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort‏
670		‎‡a Author's Hepatitis C "true" late relapse beyond 48weeks of sustained virologic response after direct acting antiviral therapy‏
670		‎‡a Author's Problems associated with the diagnosis of vitality in burned bodies.‏
670		‎‡a Author's Proximal duodenal obstruction--Bouveret's syndrome revisited.‏
670		‎‡a Author's Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.‏
670		‎‡a Author's Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data‏
670		‎‡a Author's Treatment of recurrent genotype 1 hepatitis C post-liver transplantation: single center experience with telaprevir-based triple therapy.‏
670		‎‡a Author's Undesired Final of a Student's Beer Drinking Duel‏
670		‎‡a Author's [Unexpected complication following esophageal variceal hemorrhage - Case 2/2011]‏
670		‎‡a Author's Varicella gastritis under immunosuppression: Case report of a woman after lung transplantation due to granulomatosis with polyangiitis‏
670		‎‡a wikidata authority control‏ ‎‡u https://viaf.org/processed/DNB\|1114677442‏
670		‎‡a wikidata authority control‏ ‎‡u https://viaf.org/viaf/4365147553274353800009‏
909		‎‡a (orcid) 000000018557473x‏ ‎‡9 1‏
919		‎‡a varicellagastritisunderimmunosuppressioncasereportofawomanafterlungtransplantationduetogranulomatosiswithpolyangiitis‏ ‎‡A Varicella gastritis under immunosuppression: Case report of a woman after lung transplantation due to granulomatosis with polyangiitis‏ ‎‡9 1‏
919		‎‡a unexpectedcomplicationfollowingesophagealvaricealhemorrhagecase2‏ ‎‡A [Unexpected complication following esophageal variceal hemorrhage - Case 2/2011]‏ ‎‡9 1‏
919		‎‡a undesiredfinalofastudentsbeerdrinkingduel‏ ‎‡A Undesired Final of a Student's Beer Drinking Duel‏ ‎‡9 1‏
919		‎‡a treatmentofrecurrentgenotype1hepatitis100postlivertransplantationsinglecenterexperiencewithtelaprevirbasedtripletherapy‏ ‎‡A Treatment of recurrent genotype 1 hepatitis C post-liver transplantation: single center experience with telaprevir-based triple therapy.‏ ‎‡9 1‏
919		‎‡a telaprevirbasedtripletherapyinlivertransplantpatientswithhepatitis100virusa12weekpilotstudyprovidingsafetyandefficacydata‏ ‎‡A Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data‏ ‎‡9 1‏
919		‎‡a 2generationdirectactingantiviralhepatitis100virustreatmentefficacysafetyandpredictorsofsvr12‏ ‎‡A Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.‏ ‎‡9 1‏
919		‎‡a proximalduodenalobstructionbouveretssyndromerevisited‏ ‎‡A Proximal duodenal obstruction--Bouveret's syndrome revisited.‏ ‎‡9 1‏
919		‎‡a problemsassociatedwiththediagnosisofvitalityinburnedbodies‏ ‎‡A Problems associated with the diagnosis of vitality in burned bodies.‏ ‎‡9 1‏
919		‎‡a hepatitis100truelaterelapsebeyond48weeksofsustainedvirologicresponseafterdirectactingantiviraltherapy‏ ‎‡A Hepatitis C "true" late relapse beyond 48weeks of sustained virologic response after direct acting antiviral therapy‏ ‎‡9 1‏
919		‎‡a 1generationproteaseinhibitortripletherapysvr24safetyandpredictorsofresponseinalargesinglecentercohort‏ ‎‡A First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort‏ ‎‡9 1‏
919		‎‡a feasibilityoftelaprevirbasedtripletherapyinlivertransplantpatientswithhepatitis100virussvr24results‏ ‎‡A Feasibility of telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: SVR 24 results‏ ‎‡9 1‏
919		‎‡a epidemiologyandgenotypingofpatientswithchronichepatitisbgenotypeshiftingobservedinpatientsfromcentraleurope‏ ‎‡A Epidemiology and Genotyping of Patients with Chronic Hepatitis B: Genotype Shifting Observed in Patients from Central Europe‏ ‎‡9 1‏
919		‎‡a efficacyandsafetyoftelaprevirtvrtripletherapyinareallifecohortof102patientswithhcvgenotype1interimanalysisafter24weeksoftreatment‏ ‎‡A Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment.‏ ‎‡9 1‏
919		‎‡a efficacyandsafetyoftelaprevir‏ ‎‡A Efficacy and safety of telaprevir‏ ‎‡9 1‏
919		‎‡a choledochoduodenalfistulaafterlivertransplantation‏ ‎‡A Choledochoduodenal fistula after liver transplantation.‏ ‎‡9 1‏
919		‎‡a cckinhibitstheorexigeniceffectofperipheralghrelin‏ ‎‡A CCK inhibits the orexigenic effect of peripheral ghrelin‏ ‎‡9 1‏
919		‎‡a acutekidneyinjuryinliverfailure‏ ‎‡A [Acute kidney injury in liver failure].‏ ‎‡9 1‏
943		‎‡a 201x‏ ‎‡A 2011‏ ‎‡9 1‏
946		‎‡a b‏ ‎‡9 1‏
996		‎‡2 DNB\|1032984589‏
996		‎‡2 DNB\|1169991351‏
996		‎‡2 DNB\|129270148‏
996		‎‡2 DNB\|1051821967‏
996		‎‡2 NYNYRILM\|18105‏
996		‎‡2 DNB\|143356488‏
996		‎‡2 LC\|n 2006066379‏
996		‎‡2 DNB\|107798441‏
996		‎‡2 DNB\|142345830‏
996		‎‡2 PLWABN\|9810626018105606‏
996		‎‡2 DNB\|1260802477‏
996		‎‡2 DNB\|135068703‏
996		‎‡2 DNB\|119867877‏
996		‎‡2 DBC\|87097969832962‏
996		‎‡2 DNB\|123406579‏
996		‎‡2 LIH\|LNB:C1Z_r_;=B_m_‏
996		‎‡2 DNB\|131867652‏
996		‎‡2 SUDOC\|136940749‏
996		‎‡2 DNB\|1210432390‏
996		‎‡2 DNB\|1053488238‏
996		‎‡2 BIBSYS\|3018944‏
996		‎‡2 SUDOC\|081973861‏
996		‎‡2 ISNI\|0000000021014955‏
996		‎‡2 LC\|no2008040601‏
996		‎‡2 RERO\|A008909782‏
996		‎‡2 LC\|no2011068613‏
996		‎‡2 DNB\|131435922‏
996		‎‡2 BNF\|15025797‏
996		‎‡2 ISNI\|0000000078518097‏
996		‎‡2 PLWABN\|9810669380605606‏
996		‎‡2 DNB\|1073519821‏
996		‎‡2 LC\|no 92028491‏
996		‎‡2 DNB\|136289452‏
996		‎‡2 ISNI\|0000000022240022‏
996		‎‡2 ISNI\|0000000453074775‏
996		‎‡2 LC\|n 2022049150‏
996		‎‡2 DNB\|129057894‏
996		‎‡2 PLWABN\|9810564073605606‏
996		‎‡2 DNB\|1187167797‏
996		‎‡2 DNB\|1138046892‏
996		‎‡2 ISNI\|0000000017036019‏
996		‎‡2 ISNI\|0000000022548334‏
996		‎‡2 DNB\|1123750556‏
996		‎‡2 ISNI\|000000005831613X‏
996		‎‡2 SZ\|1138046892‏
996		‎‡2 DNB\|1064963080‏
996		‎‡2 DNB\|117543194X‏
996		‎‡2 DNB\|1187984310‏
996		‎‡2 ISNI\|0000000073208751‏
996		‎‡2 ISNI\|0000000083993669‏
996		‎‡2 DNB\|130599875‏
996		‎‡2 DNB\|1024261425‏
996		‎‡2 DNB\|1052857426‏
996		‎‡2 DNB\|135755956‏
996		‎‡2 DNB\|129019484X‏
996		‎‡2 DE633\|pe30010308‏
996		‎‡2 RERO\|A003968476‏
996		‎‡2 RERO\|A003968477‏
996		‎‡2 LC\|no2007035514‏
996		‎‡2 ISNI\|0000000059609217‏
996		‎‡2 DNB\|1249454794‏
996		‎‡2 ISNI\|0000000057006922‏
996		‎‡2 BIBSYS\|1592544500143‏
996		‎‡2 DNB\|129559725‏
996		‎‡2 DNB\|1272551741‏
996		‎‡2 J9U\|987007273457005171‏
996		‎‡2 DE633\|pe41025504‏
996		‎‡2 SUDOC\|06731533X‏
996		‎‡2 ISNI\|0000000027087936‏
996		‎‡2 RERO\|A012132256‏
996		‎‡2 DNB\|128559985‏
996		‎‡2 PLWABN\|9812072847005606‏
996		‎‡2 J9U\|987007520808905171‏
996		‎‡2 BNF\|12388653‏
996		‎‡2 LC\|nr 97001160‏
996		‎‡2 DNB\|133513394‏
996		‎‡2 RERO\|A023768298‏
996		‎‡2 DNB\|1218635967‏
996		‎‡2 ISNI\|0000000358350858‏
996		‎‡2 LC\|nb2001028676‏
996		‎‡2 NTA\|181424010‏
996		‎‡2 ISNI\|0000000115131909‏
996		‎‡2 DNB\|1123735867‏
996		‎‡2 DNB\|1053501323‏
996		‎‡2 DNB\|1052857760‏
996		‎‡2 DNB\|11805368X‏
996		‎‡2 DNB\|1164710036‏
996		‎‡2 LC\|n 00013713‏
996		‎‡2 ISNI\|0000000046001616‏
996		‎‡2 NKC\|xx0087577‏
996		‎‡2 DNB\|1082760277‏
996		‎‡2 ISNI\|0000000434499911‏
996		‎‡2 DNB\|130458058‏
996		‎‡2 DNB\|1157774091‏
996		‎‡2 DNB\|133276562‏
996		‎‡2 SUDOC\|032964005‏
996		‎‡2 BIBSYS\|90166457‏
996		‎‡2 PLWABN\|9810583705005606‏
996		‎‡2 DNB\|1205030360‏
996		‎‡2 DNB\|1051507812‏
996		‎‡2 DNB\|1084656469‏
996		‎‡2 BIBSYS\|10032637‏
996		‎‡2 NTA\|084988088‏
996		‎‡2 LC\|n 88231613‏
996		‎‡2 LC\|n 86852271‏
996		‎‡2 NKC\|jo2014810159‏
996		‎‡2 ISNI\|0000000022978393‏
996		‎‡2 NTA\|074596470‏
996		‎‡2 DE633\|pe51014422‏
996		‎‡2 DNB\|1334536368‏
996		‎‡2 ISNI\|0000000055474255‏
996		‎‡2 LC\|no2009075906‏
996		‎‡2 NSK\|000448289‏
996		‎‡2 JPG\|500355870‏
996		‎‡2 DNB\|121341852‏
996		‎‡2 RERO\|A024572140‏
996		‎‡2 NDL\|001268671‏
996		‎‡2 DNB\|127981888‏
996		‎‡2 JPG\|500332477‏
996		‎‡2 J9U\|987007443673505171‏
996		‎‡2 DE633\|pe41012606‏
996		‎‡2 DNB\|1298038332‏
996		‎‡2 LC\|n 92119175‏
996		‎‡2 NII\|DA12880794‏
996		‎‡2 LC\|n 2009017909‏
996		‎‡2 ISNI\|0000000392468796‏
996		‎‡2 NUKAT\|n 2013197703‏
996		‎‡2 BNF\|14412867‏
996		‎‡2 LIH\|LNB:C4Z_b_;=BZ‏
996		‎‡2 DNB\|117297607‏
996		‎‡2 SELIBR\|jzw91cxqgkbxr85z‏
996		‎‡2 ISNI\|0000000019926875‏
996		‎‡2 DNB\|1157496865‏
996		‎‡2 ISNI\|0000000029645794‏
996		‎‡2 DE633\|pe30003335‏
996		‎‡2 ISNI\|0000000054507780‏
996		‎‡2 ISNI\|0000000392212248‏
996		‎‡2 NUKAT\|n 2017055119‏
996		‎‡2 ISNI\|0000000408481160‏
996		‎‡2 ISNI\|0000000091150450‏
996		‎‡2 DE633\|pe30010113‏
996		‎‡2 LC\|n 99001925‏
996		‎‡2 NUKAT\|n 2021210725‏
996		‎‡2 NKC\|ola2014825028‏
996		‎‡2 DE633\|pe30017156‏
996		‎‡2 BNF\|16648547‏
996		‎‡2 DNB\|1230421718‏
996		‎‡2 DNB\|1322946175‏
996		‎‡2 NUKAT\|n 2023092188‏
996		‎‡2 DNB\|1096252619‏
997		‎‡a 0 0 lived 0 0‏ ‎‡9 1‏
998		‎‡a Werner, Christoph Reinhold‏ ‎‡2 PLWABN\|9812424695705606‏ ‎‡3 exact title: (1.00, 'epidemiologyandgenotypingofpatientswithchronichepatitisbgenotypeshiftingobservedinpatientsfromcentraleurope', 'epidemiologyandgenotypingofpatientswithchronichepatitisbgenotypeshiftingobservedinpatientsfromcentraleurope')‏
998		‎‡a Werner, Christoph Reinhold‏ ‎‡2 DNB\|1114677442‏ ‎‡3 suggested‏ ‎‡3 standard number‏

VIAF

Virtual International Authority File

Search